GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (FRA:VE11) » Definitions » Deferred Policy Acquisition Costs

Aravive (FRA:VE11) Deferred Policy Acquisition Costs


View and export this data going back to 2014. Start your Free Trial

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Aravive (FRA:VE11) Business Description

Industry
Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.